BiOptix to Sponsor Scientific Briefing at Antibody Engineering and Therapeutics Summit
BOULDER, Colo. and HUNTINGTON BEACH, Calif. – BiOptix, exhibiting this week at the Antibody Engineering and Therapeutics Summit, will sponsor a scientific briefing entitled: "Slow Off-Rate Modified DNA Aptamer Inhibitors of IL-6 Signaling". BiOptix is proud to sponsor Dr. Steve Wolk of Somalogic's discussion of slow off-rate modified aptamers (SOMAmers) -- affinity reagents generated through an iterative selection process using modified nucleotides to confer protein-like properties and higher affinity interactions than observed for aptamers alone. In this presentation, SOMAmers generated to IL-6 were further affinity-optimized and characterized by x-ray crystallography and surface plasmon resonance (SPR).Â
BiOptix will be at the Antibody Engineering Summit showcasing the features and utility of the 404pi SPR instrument. According to Ken Wilczek, Vice President of Worldwide Marketing and Business Development, "We plan to increase our overall visibility at trade shows for 2015, and incorporating scientific briefings into our marketing plan is a step in that direction. Our customers and business partners are generating exciting data and leading edge scientific publications using our innovative SPR instrument platform and we would like to communicate that value proposition to a wider audience." Additional event details can be found at: www.bioptix.com
About BiOptix
BiOptix Diagnostics is a privately held firm based in Boulder, Colorado, with leading investments from Boulder Ventures, Remeditex and Rusnano. BiOptix has developed a new class of analytical biosensor instrumentation utilizing a patented high-throughput label-free technology known as ESPR - Enhanced Surface Plasmon Resonance. BiOptix instrumentation allows researchers to study label-free protein-protein and protein-small molecule interaction--with high sensitivity and high throughput. Applications include: Protein-small molecule interactions, protein-protein kinetics, antibody affinities and epitope mapping, oligosaccharide characterization, nucleic acid (DNA-DNA or DNA-RNA) hybridization and biomolecule concentration measurements. Additional information about BiOptix and our products can be found at: www.bioptix.com
BiOptix:Â Kinetics with Confidence.
Source
BiOptix
Contact: Ken Wilczek, ken@bioptix.com, 303-545-5550 x125
Web Site: http://www.bioptix.com
